These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7329507)

  • 1. [Pathogenetic treatment of various hereditary extrapyramidal disorders with new drugs].
    Markowa ED; Hausmanowa-Petrusewicz I; Alijewa LM; Friedman A; Insarowa NG
    Neurol Neurochir Pol; 1981; 15(4):403-6. PubMed ID: 7329507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Problems of the clinical polymorphism of hereditary extrapyramidal disorders].
    Markowa ED; Iwanowa-Smolenskaja JA; Alijewa LM; Członkowska A
    Neurol Neurochir Pol; 1981; 15(4):373-6. PubMed ID: 7329504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG; Tanner CM; Gilley DW; Klawans HL
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Characteristics of central neurotransmitter metabolism in hereditary extrapyramidal disorders].
    Iwanowa-Smolenskaja JA; Barchatowa WP
    Neurol Neurochir Pol; 1981; 15(4):377-80. PubMed ID: 7329505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA; Gilhus NE
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
    Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
    Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison between results achieved by administering L-dopa and Sinemet in parkinsonism in the light of our records].
    Szulc-Kuberska J; Niewodniczy A; Poźniak-Patewics E; Wolczyk-Orzechowska M
    Neurol Neurochir Pol; 1975; 9(5):611-5. PubMed ID: 1186952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathogenesis and treatment of torsion dystonia].
    Barkhatova VP; Markova ED
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1978; 78(8):1121-8. PubMed ID: 696099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [L-dopa with inhibitor in the treatment of parkinsonian syndrome-results of long-term observations].
    Wasilewski R
    Neurol Neurochir Pol; 1981; 15(4):411-6. PubMed ID: 7035990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
    Jankovic J; Schwartz K; Vander Linden C
    Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
    Rodnitzky RL; Dickins QS; Dobson J
    Neurology; 1989 Nov; 39(11 Suppl 2):92-5; discussion 95. PubMed ID: 2586769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
    Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.